Ginkgo Bioworks Holdings (DNA) Operating Expenses (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has 7 years of Operating Expenses data on file, last reported at $90.8 million in Q1 2026.

• Quarterly Operating Expenses fell 23.79% year-over-year to $90.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $439.0 million (down 36.38% YoY) and the FY2025 annual result came in at $485.4 million, down 38.3% from the prior year.
• Operating Expenses fell to $90.8 million in Q1 2026, from $104.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $843.8 million in Q1 2022 to a low of $90.8 million in Q1 2026.
• A 5-year average of $302.8 million and a median of $215.9 million in 2024 frame the typical range for Operating Expenses.
• The widest YoY moves for Operating Expenses: up 733.67% in 2022, down 82.05% in 2022.
• Tracing DNA's Operating Expenses over 5 years: stood at $329.1 million in 2022, then slumped by 35.33% to $212.9 million in 2023, then slumped by 30.73% to $147.5 million in 2024, then decreased by 29.37% to $104.1 million in 2025, then dropped by 12.77% to $90.8 million in 2026.
• The last three Operating Expenses figures came in at $90.8 million (Q1 2026), $104.1 million (Q4 2025), and $128.9 million (Q3 2025), per Business Quant data.